Category: biotech

.Novo Nordisk is continuing its own press right into genetic medications, accepting compensate NanoVation Therapies approximately $600 million to team up on approximately seven plans

.Novo Nordisk has actually axed its once-monthly double GLP-1/ GIP receptor agonist, ending (PDF) progression of a drug applicant that it singled out as a

.Novo Nordisk has actually raised the top on a phase 1 trial of its dental amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1%

.Novartis levels a brand new outpost in its partnership with Voyager Therapeutics, paying $15 million to occupy its option on an unfamiliar capsid for make

.Novartis has actually had some rotten luck with bispecific antibodies in the past, however determining by the pharma’s newest bargain it still has faith in

.Do not quit Monte Rosa Rehabs right now. The Boston-based biotech is having a ball after signing a deal with Novartis cost $150 million for

.Noema Pharma has racked up a stage 2a succeed for its Tourette disorder medicine candidate, disclosing appeal the key and vital secondary endpoints in a

.Bayer put on hold the phase 3 trial for its own aspect XIa prevention asundexian behind time in 2013 after the medicine revealed “substandard efficacy”

.Tissue therapy biotech Endurance Bio has actually unveiled with $17.2 million as well as a mission of targeting immune system conditions through flexing and also

.Neurocrine Biosciences’ schizophrenia course pivot has actually neglected. The biotech was actually unable to reproduce the cognition indicator it viewed in an earlier midphase study,